AIM
CTMX icon

Alambic Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Alambic Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-24,400
Closed -$694K – 371
2018
Q1 		$694K Buy
24,400
+7,600
+45% +$217K 0.1% 280
2017
Q4 		$355K Buy
+16,800
New +$348K 0.04% 359

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Alambic Investment Management's CTMX Position: Q2 2018 in Review

Alambic Investment Management sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 24,400 shares — an estimated $694K sold.

Alambic Investment Management first reported a position in CTMX in Q4 2017 and held it in 2 quarters. The position peaked at $694K in Q1 2018. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

  • Alambic Investment Management reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 24,400 CytomX Therapeutics shares in Q2 2018, an estimated $694K.
  • Alambic Investment Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 2 quarters.
  • Alambic Investment Management's CytomX Therapeutics position peaked at $694K in Q1 2018.
  • 142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.